Local IFNα enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse
Background Tumor relapse constitutes a major challenge for anti-tumoral treatments, including immunotherapies. Indeed, most cancer-related deaths occur during the tumor relapse phase.Methods We designed a mouse model of tumor relapse in which mice transplanted with E7+ TC1 tumor cells received a sin...
Saved in:
| Main Authors: | Maxime Thoreau, Fabienne Regnier, Ludger Johannes, Estelle Dransart, Alain Trautmann, Nadege Bercovici, Marion v Guerin, Lene Vimeux, Matthieu Benard, Hweixian L Penny |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000996.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tumor Delivery of Ultrasound Contrast Agents Using Shiga Toxin B Subunit
by: Olivier Couture, et al.
Published: (2011-03-01) -
Myeloid cell‐based delivery of IFN‐γ reprograms the leukemia microenvironment and induces anti‐tumoral immune responses
by: Adele Mucci, et al.
Published: (2021-08-01) -
Tumor vaccines: Toward multidimensional anti-tumor therapies
by: Yuanfang Tan, et al.
Published: (2023-12-01) -
Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor
by: Wenpeng Cai, et al.
Published: (2025-08-01) -
IFNλ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFNα treatment
by: Sophia Davidson, et al.
Published: (2016-08-01)